Stoke Therapeutics (NASDAQ:STOK) – Equities research analysts at Wedbush issued their FY2024 earnings estimates for shares of Stoke Therapeutics in a report issued on Monday, March 23rd. Wedbush analyst L. Chico expects that the company will post earnings per share of ($1.95) for the year. Wedbush currently has a “Outperform” rating and a $31.00 target price on the stock.
Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.21.
Several other equities research analysts have also issued reports on the stock. Cowen reaffirmed a “buy” rating on shares of Stoke Therapeutics in a report on Monday. JPMorgan Chase & Co. decreased their price target on shares of Stoke Therapeutics from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, December 3rd. Zacks Investment Research lowered shares of Stoke Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Stoke Therapeutics in a report on Monday, December 9th. Finally, BidaskClub raised shares of Stoke Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 1st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $34.57.
Shares of Stoke Therapeutics stock opened at $22.65 on Thursday. The firm has a market capitalization of $698.78 million and a PE ratio of -12.58. The firm’s 50 day moving average is $24.82 and its 200 day moving average is $25.12. Stoke Therapeutics has a 1 year low of $15.82 and a 1 year high of $39.04.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Stoke Therapeutics by 1.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 52,900 shares of the company’s stock worth $1,499,000 after purchasing an additional 546 shares during the period. Bank of Montreal Can acquired a new position in shares of Stoke Therapeutics in the 4th quarter worth approximately $33,000. Altshuler Shaham Ltd acquired a new position in shares of Stoke Therapeutics in the 4th quarter worth approximately $35,000. UBS Group AG lifted its position in shares of Stoke Therapeutics by 50.6% in the 4th quarter. UBS Group AG now owns 9,149 shares of the company’s stock worth $259,000 after purchasing an additional 3,075 shares during the period. Finally, Barclays PLC lifted its position in shares of Stoke Therapeutics by 63.9% in the 4th quarter. Barclays PLC now owns 9,836 shares of the company’s stock worth $278,000 after purchasing an additional 3,835 shares during the period.
In other Stoke Therapeutics news, COO Huw M. Nash sold 49,143 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $25.89, for a total transaction of $1,272,312.27. Following the sale, the chief operating officer now directly owns 6,324 shares of the company’s stock, valued at approximately $163,728.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Further Reading: What does an inverted yield curve signify?
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.